INTRODUCTION
Encephalocele is a severe birth defect of the skull and brain with a median prevalence of 0.1-0.3 per 1000 births, although with geographical variation (1) . The meninges, with/without brain tissue, herniate outside the skull as a sac, exposing the brain to potential damage both pre-and post-natally. Despite surgical repair soon after birth, later health problems are common, including hydrocephalus, epilepsy and learning difficulties. Encephaloceles emerge along the skull midline, with variation in rostro-caudal location which can be frontoethmoidal, parietal, occipital or cervical. Generally, the prognosis worsens with posterior location, size of sac and increasing amount of herniated brain tissue (2) .
Although most cases are sporadic and of unknown causation, encephalocele can form part of a syndrome as in trisomy 18, Knoblock syndrome (COL18A1 mutation), amniotic band syndrome and warfarin embryopathy (3) . Occipital encephalocele is best known as part of Meckel syndrome (overlapping with Joubert syndrome), in which individuals also exhibit polydactyly, polycystic kidneys and biliary defects. In recent years, mutations in several genes (e.g. MKS1, MKS2 (TMEM216), MKS3 (TMEM67), CEP290, RPGRIP1L) have been identified in various forms of Meckel syndrome (4) . Cellular analysis of the MKS proteins has demonstrated a key role in the structure and function of primary cilia, and Meckel syndrome is thus now classified as a ciliopathy.
Mice that incorporate mutations of some of the genes responsible for Meckel syndrome display biliary, limb and kidney defects resembling the human syndrome, as well as defective ciliary structure and/or function (5-7). While failure of cranial neural tube closure was described in a proportion of Tmem67 (MKS3) null mice (8) , none of the mouse models appear to exhibit herniation of brain tissue outside the skull, which would represent an encephalocele.
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While often classified as a 'neural tube defect' (NTD) (4;9) , the embryonic/fetal pathogenesis of encephalocele is less well understood than for other NTDs, particularly anencephaly and open spina bifida. The latter conditions result from defective closure of the neural tube (i.e.
primary neurulation), as demonstrated by studies of NTD pathogenesis in mouse mutants (10) . Of the many (> 240) mouse mutants so far described, very few display a phenotype corresponding to encephalocele (11) . Hence, the mouse data do not yet conclusively shed light on whether encephalocele is a primary neurulation defect or a post-neurulation anomaly, such as herniation of the closed neural tube through a skull defect.
Recently, encephalocele was identified as part of a 'cluster' of NTDs in the pregnancies of HIV-positive Botswanan women exposed to the anti-retroviral drug dolutegravir from the time of conception (12) . NTDs in this cluster comprised one case each of encephalocele, anencephaly, myelomeningocele and iniencephaly, and occurred with a prevalence of 9.4 per 1000 births (4 out of 426 infants). This is a markedly elevated prevalence, compared with 1.2 per 1000 or less in comparator groups that were not exposed to dolutegravir from conception. An urgent need is to determine whether this cluster of NTDs represents a causal association with dolutegravir. However, this is hampered by uncertainty over whether encephalocele can share causation with 'open' NTDs: anencephaly and myelomeningocele.
Here we describe a mouse model of encephalocele resulting from conditional deletion of Rac1, a small GTPase of the Rho family, in the non-neural (surface) ectoderm of the embryo. These mice exhibit open spina bifida (myelomeningocele equivalent) and, in some cases exencephaly (anencephaly equivalent) (13) (14) (15) . We show that a large proportion of these mice also develop occipito-parietal encephalocele, detectable from embryonic day (E) 13.5 onwards. The encephalocele displays a fully closed neural tube at the level of the lesion, with an associated overlying skull defect. Hence, encephalocele is a post-neurulation anomaly that can be caused by the same genetic defect as open spina bifida and exencephaly/anencephaly. Rac1 expression (denoted 'Grhl3Cre-Con'; Figure 1A ). Littermates without Cre expression (Grhl3
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RESULTS
Grhl3Cre-Rac1 mutants display exencephaly or encephalocele
) were denoted 'Non-Cre' controls (Table 1 ).
Grhl3Cre-Rac1 mutants develop spina bifida at high penetrance (81%; Figure 1C , E; Table   1 ), as described previously (13) . Exencephaly ( Figure 1E ) also occurs in mutants, but at lower frequency affecting 30% (21/69) of Grhl3Cre-Rac1 embryos at E9.5 and 25% (11/44) at E10.5-13.5 (14) . Here we examined E13.5-17.5 fetuses and found exencephaly in 33% (9/27; Table 1 ). Hence, exencephaly is first seen at the stage when cranial neural tube closure is usually completed (E9.5) and persists at a relatively constant rate into later gestation.
From E13.5 onwards, we also encountered another cranial phenotype, resembling parietooccipital encephalocele ( Figure 1C ). This affected more than half (61%) of the nonexencephalic Grhl3Cre-Rac1 fetuses (41% of total fetuses) and was not seen in littermate controls (Table 1 ; Figure 1A ). Encephalocele appeared as a smooth protrusion of the cranial region, in contrast to the irregular 'mushroom-like' appearance of exencephaly (compare Figure 1C and E).
Hence, both exencephaly and encephalocele occur among mouse mutants lacking Rac1 expression in the surface ectoderm, but the two defects arise in different individuals, at 6 different developmental stages: exencephaly at neurulation, and encephalocele postneurulation.
Larger skull defects in mutants with encephalocele than exencephaly
Skull preparations showed that at E17.5 the bones of Grhl3Cre-Con fetuses are well formed and meet at the dorsal midline, prefiguring the sagittal suture ( Figure 1B and a well-defined ventricular lumen at all rostro-caudal levels of the brain, including at the levels where the overlying tissues appeared broken. This finding not only confirmed that the encephalocele does not result from a failure of neural tube closure, but also showed that the brain defects observed at E17.5 develop after the onset of encephalocele.
To more precisely pinpoint the timing of encephalocele development, we analysed Grhl3Cre-Rac1 mutant embryos at E12.5 ( Figure 3G, H) . Use of the Rosa26-EYFP reporter confirmed that, as at earlier stages (Rolo et al, 2016 ), Grhl3Cre-driven recombination at E12.5 is present in the entire dorsal surface ectoderm, but only in a variable small minority of cells in the neuroepithelium and mesenchyme ( Figure S1 ). Despite Rac1 knock-down in all surface ectoderm cells ( Figure 3H '), the tissues overlying the brain of mutant embryos were still intact at E12.5 and morphologically similar, although apparently thinner, compared with those of Grhl3Cre-Con embryos ( Figure 3G , H). We conclude that encephalocele in Grhl3Cre-Rac1 mice arises between E12.5 and E13.5, following completion of cranial neural tube closure, when the surface ectoderm and associated tissues are lost and the neural tube becomes exposed to the external environment.
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DISCUSSION
Over 240 mouse models of NTDs have been reported, mainly displaying exencephaly, spina bifida, or both (11) . To date, however, only two convincing mouse models of encephalocele have been described: the tuft mouse which involves a mutation of the Tet1 gene (20;21) and the fog mutant in which the Apaf1 gene is mutated (22) . Both display frontal encephalocele together with craniofacial defects and, in tuft mice, also lipoma. In humans, fronto-ethmoidal encephalocele is particularly found in South-East Asia (23), whereas in other geographical locations it is a less common defect than occipital encephalocele. Moreover, lipoma does not typically accompany any of the varieties of human encephalocele. The defect we describe here, in Grhl3Cre-Rac1 mutants, is the first report to our knowledge of a murine model of occipito-parietal encephalocele, and without accompanying facial defects or lipoma. It therefore represents a 'proof-of-principle' study of the origin during brain development of a type of encephalocele that is common in humans.
Even though encephaloceles are increasingly classified as post-neurulation defects, uncertainty continues over their relationship to neural tube closure. Indeed, the encephalocele in tuft mice has been described as resulting from incomplete closure of the anterior neural tube (20) . On the other hand, some authorities argue that encephalocele is a later-arising defect, resulting from incomplete fusion of the skull bones at the midline, creating a gap through which meninges and brain tissue herniate (23) . The defect in Grhl3Cre-Rac1 mutants is first detected at E13.5, approximately 4 days after anterior neural tube closure is completed, but before the beginning of skull ossification. In sharp contrast, exencephaly arises in the same mutant litters, with an onset at the stage of cranial neural tube closure.
We conclude, therefore, that encephalocele in Grhl3Cre-Rac1 mutants is neither a result of a failure in neurulation nor primarily a skull defect. Rather, it develops after neural tube closure due to a defect in the surface ectoderm, and the defect is already manifest by the time of skull formation. Despite not being the result of a skull defect, encephalocele in Grhl3Cre-Rac1 mutants is nonetheless associated with severe malformation of skull bone formation, likely explaining the later pathogenesis of human encephalocele, in which the brain and/or meninges herniate through a skull defect.
Besides the occipito-parietal location of the encephalocele, another difference between our study and the tuft and fog mouse models of frontal encephalocele, is the lack of skin coverage in Grhl3Cre-Rac1 mutants. In humans, the encephalocele sac is often skin- (12), it is perfectly plausible that cases of encephalocele, anencephaly and myelomeningocele could all be etiologically related, as alternative outcomes of faulty nervous system development in the embryo. (14) . Embryos were dissected in Dulbecco's modified Eagle's Medium (DMEM; Invitrogen) containing 10% fetal bovine serum (Sigma), and rinsed in phosphate buffered saline (PBS) prior to fixation. Embryo genotyping was by PCR of yolk sac DNA, as described (14) . Experiments were conducted according to the ARRIVE guidelines (www.nc3rs.org.uk): e.g. all analyses were performed blind to genotype which was obtained after data collection had been completed.
MATERIALS AND METHODS
Mouse procedures and experimental design
Histology and skull preparations
Embryos were fixed over several days in Bouin's solution (Sigma) or in 4% paraformaldehyde in PBS, dehydrated in an ethanol series and embedded in paraffin-wax.
Sections (5 µm thickness) were stained with Harris' haematoxylin solution and 2% Eosin Y, or Alizarin Red and Fast Green (all Sigma). Images were captured on an Axiophot2 upright microscope. For skull preparations, embryo heads were skinned and stained with Alizarin Red (0.15%) in 1% KOH and cleared with 1% KOH in 20% glycerol (18) .
mRNA in situ hybridisation
In situ hybridisation was performed on 5 µm-thick paraffin sections using a digoxigeninlabelled anti-sense RNA probe designed to detect the exons deleted in the Rac1 conditional mutant (14) . Images were captured on an Axiophot2 upright microscope.
Immunofluorescence
Embryos were fixed for 24 h in 4% paraformaldehyde in PBS, pH 7.4, at 4°C. Immunofluorescence for YFP (yellow fluorescent protein) was performed on 12 µm-thick cryosections of gelatine-embedded embryos (7.5% gelatine [Sigma] in 15% sucrose) using an anti-GFP (green fluorescent protein) rabbit polyclonal Alexa488-conjugated antibody (Life Technologies A21311) at 1:400 dilution. Anti-GFP cross-reacts with YFP. Nuclei were labelled with TO-PRO-3 (Thermo Fisher). Images were captured on an LSM880 Examiner confocal system (Carl Zeiss Ltd, UK) as previously reported (19), and linear adjustments made using Fiji software.
Statistics
Fisher's exact test was used for comparison of phenotype frequencies in Table 1 . When more than two groups were compared in multiple tests, the chance of detecting false positives was minimised by 'protecting the alpha-level': i.e. the conventional p = 0.05 critical value was divided by the number of tests. Hence, for 2 tests, p < 0.025 was interpreted as indicating p < 0.05.
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